JP2010518086A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518086A5
JP2010518086A5 JP2009549118A JP2009549118A JP2010518086A5 JP 2010518086 A5 JP2010518086 A5 JP 2010518086A5 JP 2009549118 A JP2009549118 A JP 2009549118A JP 2009549118 A JP2009549118 A JP 2009549118A JP 2010518086 A5 JP2010518086 A5 JP 2010518086A5
Authority
JP
Japan
Prior art keywords
oral dosage
dosage formulation
administration
minutes
dosing period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009549118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518086A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/001711 external-priority patent/WO2008100434A1/en
Publication of JP2010518086A publication Critical patent/JP2010518086A/ja
Publication of JP2010518086A5 publication Critical patent/JP2010518086A5/ja
Pending legal-status Critical Current

Links

JP2009549118A 2007-02-09 2008-02-08 スフェンタニルおよびナロキソンを含む経口腔投与製剤 Pending JP2010518086A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90066107P 2007-02-09 2007-02-09
US90458507P 2007-03-02 2007-03-02
PCT/US2008/001711 WO2008100434A1 (en) 2007-02-09 2008-02-08 Transoral dosage forms comprising sufentanil and naloxone

Publications (2)

Publication Number Publication Date
JP2010518086A JP2010518086A (ja) 2010-05-27
JP2010518086A5 true JP2010518086A5 (enExample) 2011-03-31

Family

ID=39472527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009549118A Pending JP2010518086A (ja) 2007-02-09 2008-02-08 スフェンタニルおよびナロキソンを含む経口腔投与製剤

Country Status (5)

Country Link
US (4) US20100010031A1 (enExample)
JP (1) JP2010518086A (enExample)
AU (1) AU2008216867B2 (enExample)
CA (1) CA2677281C (enExample)
WO (1) WO2008100434A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
DK2498771T3 (da) 2009-11-12 2014-01-27 Acacia Pharma Ltd Anvendelse af bethanechol til behandling af xerostomi
GB2476494A (en) * 2009-12-24 2011-06-29 Norwich Pharma Technologies Ltd Formulation for the sublingual delivery of sufentanil
WO2011137422A2 (en) 2010-04-30 2011-11-03 Apellis Pharmaceuticals, Inc. Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
DK2563316T3 (da) * 2010-04-30 2019-05-13 Allovate Llc Tandpasta til allergisk desensibilisering via mundslimhinder
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
SG11201401446RA (en) * 2011-08-18 2014-09-26 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US9418672B2 (en) * 2012-06-05 2016-08-16 Apple Inc. Navigation application with adaptive instruction text
WO2016191472A1 (en) 2015-05-27 2016-12-01 Mallinckrodt Llc Preparation of sufentanil citrate and sufentanil base
EP4100012A4 (en) * 2020-02-05 2024-02-07 Summit Biosciences Inc. MEDICINAL PRODUCTS INTENDED TO BE ADMINISTERED BY INTRANASAL ROUTE AND ASSOCIATED USES

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
FI943042L (fi) * 1991-12-24 1994-06-23 Yamanouchi Pharma Co Ltd Suuontelossa hajoava valmiste ja sen valmistus
CA2251623C (en) * 1996-05-13 2006-12-19 Novartis Consumer Health S.A. Buccal delivery system
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
US6103257A (en) * 1998-07-17 2000-08-15 Num-Pop, Inc. System for delivering pharmaceuticals to the buccal mucosa
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6394306B1 (en) * 2000-06-23 2002-05-28 Delsys Pharmaceutical Corp. Medication dispenser for dispensing flat dosage forms
US20020160043A1 (en) * 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US20050065175A1 (en) * 2003-09-24 2005-03-24 Xanodyne Pharmacal, Inc. Oral transmucosal methadone
PT1708686E (pt) * 2003-12-31 2011-04-20 Cima Labs Inc Forma de dosagem de fentanil oral efervescente geralmente linear e métodos de administração
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
EP1968539A2 (en) * 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
JP5632284B2 (ja) 2007-08-07 2014-11-26 エーセルアールエックス ファーマシューティカルズ， インコーポレイテッド 経口経粘膜剤形を使用する処置時の鎮静および無痛のための組成物および方法
WO2009113798A2 (en) 2008-03-14 2009-09-17 Lg Electronics Inc. Scanning method in wireless system
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same

Similar Documents

Publication Publication Date Title
JP2010518086A5 (enExample)
ATE486593T1 (de) Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
NZ587897A (en) Drug delivery systems comprising weakly basic drugs and organic acids
JP6049624B2 (ja) 苦味のある薬物のための経口用医薬フィルム製剤
NZ610701A (en) Once daily formulation of lacosamide
EA200900270A1 (ru) Системы регулируемого высвобождения и способ их приготовления
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
AR076153A1 (es) Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
JP2010510286A5 (enExample)
AR084865A1 (es) Preparacion de desintegracion rapida, comprimido dispersable por via oral
AR062647A1 (es) Formulaciones farmaceutica y metodos de uso
MY160652A (en) Pharmaceutical composition for oral administration
ATE380545T1 (de) Pharmazeutische zubereitung mit verzögerter freisetzung zur oralen wirkstoffverabreichung
JP2018039810A5 (enExample)
JP2009522376A5 (enExample)
ATE525065T1 (de) Pharmazeutische zubereitung für die orale verabreichung mit gesteuerter wirkstofffreisetzung im dünndarm und verfahren zu ihrer herstellung
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
JP2016507579A (ja) 経口投与用の咀嚼可能な組成物およびその製造方法
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
UY28457A1 (es) Nueva composición
JP2010524906A5 (enExample)